This article first appeared on GuruFocus .
Release Date: November 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
ALS Ltd ( ASX:ALQ ) reported a strong revenue growth of 13.3% to 1.7 billion, with organic growth across all business streams.
-
Underlying EBIT increased by 14.7% to 287.2 million, with an EBIT margin improvement of 20 basis points to 17.3%.
-
The company reported strong free cash flow of 303.9 million, representing 88% of underlying H1 EBITDA.
-
Life sciences division showed solid performance with a robust food result and strength in key environmental geographies.
-
ALS Ltd ( ASX:ALQ ) continues to invest in digital innovation and AI, aiming to set global standards for smart labs.
Negative Points
-
Margins in the commodities division were slightly down by 11 basis points to 28.1%, with metallurgy experiencing margin contraction.
-
Challenges in the environmental business in Latin America, particularly in Brazil, Chile, and Peru, due to pricing and operational issues.
-
The pharmaceutical business faced market-specific challenges in the Americas, impacting revenue performance.
-
The company anticipates a more subdued performance in the Americas for the life sciences division.
-
ALS Ltd ( ASX:ALQ ) is experiencing a potential lengthening of the time between raising capital and deploying it, affecting exploration activities.
Q & A Highlights
Q: Can you expand on the regional commentary for the commodities business, particularly regarding sample flows by region? A: Malcolm Dean, CEO, noted improvements across most regions, including Africa, Australia, Asia, and South America. North America showed recovery at the start of the traditional season. The uptick is primarily driven by majors and mid-tiers, with juniors showing improvement but not yet significantly impacting volumes.
Q: Could you provide more color on the challenges in Latin America, particularly in Mexico? A: Malcolm Dean explained that while Mexico is performing better than expected, challenges in Latin America are primarily in the environmental business, not pharma. Brazil, Chile, and Peru face pricing challenges and operational issues, which are being addressed.
Q: Regarding the life sciences first half margin, which was up 74 basis points, why is the full-year uplift guidance still 20 to 40 basis points? A: Stuart Hadron, CFO, mentioned that the guidance reflects conservatism due to some moving parts in life sciences that need attention. The company is cautious as they work on fixing these issues.
Q: Are there any potential acquisitions planned, and is the focus still on bolt-ons rather than transformational deals? A: Malcolm Dean confirmed that the focus remains on bolt-on acquisitions to protect, extend, and expand the portfolio. While there are discussions about industry consolidation, the company is concentrating on strategic bolt-ons in specific geographies and services.
Q: How should we think about the reclassification of costs, particularly regarding restructuring at York and Wesley? A: Stuart Hadron explained that the reclassification aims to improve visibility and accountability. The expected costs are around 6 to 8 million at the end of the fiscal year. The change aligns internal and external reporting and emphasizes the recurring nature of these costs.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
